Aileron Therapeutics, Inc.
ALRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $2 | $4 | $3 | $3 |
| G&A Expenses | $4 | $3 | $3 | $2 |
| SG&A Expenses | $4 | $3 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $7 | $6 | $6 |
| Operating Income | -$5 | -$7 | -$6 | -$43 |
| % Margin | – | – | – | -33,965.9% |
| Other Income/Exp. Net | -$0 | $0 | $0 | $2 |
| Pre-Tax Income | -$6 | -$7 | -$6 | -$41 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$7 | -$6 | -$41 |
| % Margin | – | – | – | -32,524.6% |
| EPS | -0.21 | -0.28 | -0.25 | -2.07 |
| % Growth | 25% | -12% | 87.9% | – |
| EPS Diluted | -0.21 | -0.28 | -0.25 | -2.07 |
| Weighted Avg Shares Out | 26 | 0 | 22 | 20 |
| Weighted Avg Shares Out Dil | 26 | 0 | 22 | 20 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$6 | -$7 | -$6 | -$41 |
| % Margin | – | – | – | -32,527.8% |